Brightsurf Science News and Current Science News Events
 
Email a Friend Send to a friend
Printer Friendly Print Hormone drug type makes survival difference in advanced breast cancer

Hormone drug type makes survival difference in advanced breast cancer

January 31, 2007

Aromatase inhibitors, a type of hormone therapy used to treat advanced breast cancer in postmenopausal women, result in a small but significant increase in overall survival when compared to other hormone treatments, according to a new systematic review of studies.

In addition, aromatase inhibitors — drugs known as Arimidex, Aromasin and Femara — are less likely to cause blood clots and vaginal bleeding than other hormone treatments, said review co-author Judith Bliss of the Institute of Cancer Research in London.




The review analyzed 30 studies involving the treatment of advanced breast cancer, encompassing more than 10,000 postmenopausal women.

Bliss and colleagues were surprised at how few of the reviewed studies presented data on overall survival for women taking aromatase inhibitors. "Survival data was only available for about half of the women," Bliss said.

The available data showed an 11 percent reduction in the risk of death compared to women not receiving aromatase inhibitors.

The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

The treatment of advanced breast cancer in women who have gone through menopause usually involves a combination of surgery, radiation, chemotherapy, hormonal and biological therapies. In many breast cancers, estrogen stimulates tumor growth. Aromatase inhibitors work by limiting a woman's production of estrogen.

Several aromatase inhibitors, including anastrozole (Arimidex), exemestane (Aromasin) and letrozole (Femara) have been available for clinical use for the past decade or so.

Other breast cancer treatments that also affect estrogen include tamoxifen and progestins. Tamoxifen is the most widely used hormonal treatment in advanced breast cancer; however, it carries a risk of blood clots and other rare but potentially serious side effects.

Bliss said that the review found very little reliable data in the trials comparing the effectiveness of the different available aromatase inhibitors. "The promotion of one individual drug over another is not evidence-based and should be avoided," the authors said.

In general, women taking aromatase inhibitors had about the same risk of experiencing hot flashes as those receiving tamoxifen. However, they reported more nausea, vomiting and diarrhea when compared to patients receiving the progestin drug megestrol acetate and to a lesser extent, when compared with patients receiving tamoxifen.

Patients taking aromatase inhibitors had a decreased risk of vaginal bleeding and blood clots compared to those using other hormonal therapies.

Safety data were difficult to analyze, Bliss said: "The picture is patchy due to poor quality of adverse event reporting and different study endpoints," in the various trials.

However, "the review findings do confirm modest, but real therapeutic benefits from the use of aromatase inhibitors in a variety of clinical settings," Bliss said.

Edith Perez, M.D., an oncologist with the Multidisciplinary Breast Cancer Program at the Mayo Clinic in Jacksonville, Fla., said, "The results of the review are not a surprise. These are good drugs and they have positively impacted the lives of patients with breast cancer." Perez is not associated with the review.

Perez believes that aromatase inhibitors are the first drug of choice for hormonal treatment of advanced breast cancer in postmenopausal women. "They have a slightly improved efficacy over tamoxifen, and they have a much lower rate of blood clots in the legs and lungs," she said. "Aromatase inhibitors carry almost no risk of uterine cancer, and while that rarely happens with tamoxifen, it does happen."

On the other hand, Perez said that aromatase inhibitors do carry a risk of increased joint aches and, more importantly, may cause bone loss. "The majority of patients do very well but we recommend patients have bone density tests before using these drugs. I would probably not use aromatase inhibitors in a patient with severe osteoporosis."

While per-tablet cost of aromatase inhibitors is higher than tamoxifen, Perez said that they are still cost-effective because they have fewer side effects requiring treatment and they result in increased overall survival.

"It's no question that these drugs are better for patients when compared with other hormone therapies," Perez said.

Center for the Advancement of Health



Related Aromatase Inhibitor News Articles Aromatase Inhibitor News and Current Aromatase Inhibitor Events RSS Aromatase Inhibitor News and Current Aromatase Inhibitor Events RSS
Risk assessment plays key role in long-term treatment of breast cancer
Breast cancer patients and their physicians may make more informed, long-term treatment decisions using risk assessment strategies to help determine probability of recurrence.

Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
Gefitinib, the once-promising drug formerly approved as a second line treatment for lung cancer, also known as Iressa, enhanced the effectiveness of hormonal therapy for the treatment of specific types of metastatic breast cancer.

13 percent of women stop taking breast cancer drug because of side effects, U-M study finds
More than 10 percent of women with breast cancer stopped taking a commonly prescribed drug because of joint and muscle pain, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

Letrozole following tamoxifen may benefit women with breast cancer
Switching to the drug letrozole following 5 years of treatment with tamoxifen reduces the risk of hormone-dependent breast cancer recurrence, but not overall survival, among postmenopausal women.

Leading cancer doctor calls for new guidelines to control early reporting from clinical trials
Hamburg, Germany: A leading breast cancer doctor is urging researchers to consider changing the guidelines that govern whether clinical trials should be stopped prematurely, as she believes that current practice could be damaging research efforts. Dr Martine Piccart, head of the chemotherapy unit at the Institut Jules Bordet, Brussels, Belgium, is putting proposals for new guidelines to the Breast International Group (BIG) and, if BIG agrees, the issue would be discussed with the North American Breast Intergroup. She said that breast cancer research had not been well served by trials of adjuvant therapies aimed at preventing cancer returning, which had reported their results early, because t

Exemestane beats tamoxifen in first phase III head to head trial in advanced breast cancer
Hamburg, Germany: The first results from the world's only phase III trial to compare tamoxifen with the newer hormone treatment exemestane in advanced breast cancer shows that exemestane is safe, superior and lengthens progression-free survival. The median progression-free survival for patients taking exemestane was 10.9 months compared with 6.7 months for those taking tamoxifen. Complete and partial response rates were also higher in the exemestane arm with 7.4% responding completely and 36.8% partially, compared to 2.6% of tamoxifen patients completely responding and 26.6% partially responding. Dr Robert Paridaens will tell delegates at the 4th European Breast Cancer Conference today (Thu

New evidence eases some concerns about bone fracture risk with breast cancer drug
Copenhagen, Denmark: New evidence about the breast cancer drug anastrozole (Arimidex) shows that the incidence of a major side-effect - bone fractures - appears to stabilise after reaching a peak at two years of treatment, easing some of the concerns about the drug. This finding is the latest to come from evidence provided by the world's largest international study of breast cancer treatment, the ATAC[1] trial, which compared the aromatase inhibitor anastrozole with breast cancer's current gold standard hormone treatment tamoxifen, and with both treatments combined. The trial, involving more than 9,000 post menopausal women in 21 countries, last year revealed that over a median follow-up of

New test can identify patients who may suffer serious late toxicity from radiotherapy
Radiotherapists in Switzerland have developed a fast test that can be used immediately on patients to discover whether they are likely to suffer serious late onset side effects from radiation.
More Aromatase Inhibitor News Articles


Aromatase Inhibitors (Milestones in Drug Therapy)

Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen...

Concerns crop up about aromatase inhibitors. (Adjuvant Therapy for Breast Cancer).: An article from: Family Practice News
by Bruce Jancin

This digital document is an article from Family Practice News, published by International Medical News Group on February 15, 2003. The length of the article is 890 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web...



Effects of the fungicide prochloraz on the sexual development of zebrafish (Danio rerio) [An article from: Comparative Biochemistry and Physiology, Part C]
by K. Kinnberg, H. Holbech, G.I. Petersen, Bjerregaar

This digital document is a journal article from Comparative Biochemistry and Physiology, Part C, published by Elsevier in 2007. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.Description: Some chemicals have the potential to adversely affect sexual development through multiple endocrine...

Anastrozole seen as first-line breast Ca therapy: anastrozole showed significant advantages over tamoxifen in time to local and distant recurrence.(Women's ... An article from: Family Practice News
by Bruce Jancin

This digital document is an article from Family Practice News, published by International Medical News Group on February 1, 2005. The length of the article is 712 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Aromatase inhibitors aid cancer survival.(Women's Health): An article from: Internal Medicine News
by Jane Salodof MacNeil

This digital document is an article from Internal Medicine News, published by Thomson Gale on September 1, 2006. The length of the article is 439 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:...

Aromatase inhibitor impressive against breast ca.(Adjuvant Therapy): An article from: Internal Medicine News
by Bruce Jancin

This digital document is an article from Internal Medicine News, published by International Medical News Group on February 15, 2004. The length of the article is 979 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web...

Tamoxifen-aromatase inhibitor combo improves Ca outcomes.(News): An article from: OB GYN News
by Bruce Jancin

This digital document is an article from OB GYN News, published by International Medical News Group on February 1, 2005. The length of the article is 609 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Zoledronic acid protects bone in breast Ca patients: prophylactic treatment may avert osteoporosis and fractures resulting from aromatase inhibitor therapy.(Women's ... An article from: Internal Medicine News
by Bruce Jancin

This digital document is an article from Internal Medicine News, published by International Medical News Group on March 1, 2005. The length of the article is 695 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Tamoxifen alone discouraged as adjuvant Tx.(Gynecology): An article from: OB GYN News
by Diana Mahoney

This digital document is an article from OB GYN News, published by International Medical News Group on May 1, 2005. The length of the article is 1112 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Aromatase Inhibitors for the Treatment of Breast Cancer

© 2008 BrightSurf.com